PDCD1 and cancer: In other words, T-cell activity is inhibited by the binding of the immune checkpoint proteins PD-1 and PD-L1, making it difficult to predict the efficacy of cancer treatments (Lei et al., 2020; Liu et al., 2016; Wei et al., 2019).